COMPANY
Coherus Oncology
Coherus Oncology is listed on ClinicalTrials.gov as the lead sponsor of 18 studies; the most recently updated is “Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma” (Phase 2, terminated), in Hepatocellular Carcinoma. From public records Source · Oct 12, 2026
Since the raise (Feb 17, 2026): 7 of 7 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Oncology Account Manager | Miami, FL | Oct 22, 2026 | Oct 23, 2026 |
| Oncology Account Manager | Philadelphia, PA | Oct 12, 2026 | Oct 12, 2026 |
| Oncology Account Manager | Atlanta, GA | Sep 10, 2026 | Oct 9, 2026 |
| Oncology Account Manager | Columbus, OH | Sep 3, 2026 | Oct 9, 2026 |
| Senior Manager, Translational Medicine Sample Logistics | Redwood City, CA | Aug 5, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (7 open jobs at last check). source ↗
- Raise Follow-on offering: $50.1M (total, as published), announced Feb 17, 2026. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 1: A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors source ↗
- Trial start Phase 1: A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors source ↗
- Trial start Phase 2: A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma source ↗
- Trial start Phase 4: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer source ↗
- Trial start Phase 1: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1: Study of CHS-114 in Participants With Advanced Solid Tumors source ↗
- Trial start Phase 2: Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma source ↗
- Trial start Phase 2: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer source ↗
- Trial start —: An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca source ↗
- Trial start Phase 1: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1: Study of SRF617 in Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1: Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta source ↗
- Trial start Phase 3: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis source ↗
- Trial start Phase 3: A Long Term Safety Extension Study (CHS-0214-05) source ↗
- Trial start Phase 1: Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® source ↗
- Trial start Phase 1: Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim) source ↗
- Trial start Phase 3: Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) source ↗
- Trial start Phase 3: Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) source ↗
Upcoming milestones
- 2027-09 (ESTIMATED) · Phase 2 · A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma · NCT06679985
- 2027-12 (ESTIMATED) · Phase 4 · A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer · NCT06457503
- 2028-01 (ESTIMATED) · Phase 1 · A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors · NCT06657144
- May 30, 2028 (ESTIMATED) · Phase 1 · A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors · NCT06389526
Open jobs 7
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Oncology Account Manager | Miami, FL | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Oncology Account Manager | Philadelphia, PA | Oct 12, 2026 | Oct 12, 2026 | Mid |
| Oncology Account Manager | Atlanta, GA | Sep 10, 2026 | Oct 9, 2026 | Mid |
| Oncology Account Manager | Columbus, OH | Sep 3, 2026 | Oct 9, 2026 | Mid |
| Senior Manager, Translational Medicine Sample Logistics | Redwood City, CA | Aug 5, 2026 | Oct 9, 2026 | Senior |
| Oncology Account Manager | New York | Jul 13, 2026 | Oct 9, 2026 | Mid |
| Associate Director/Director, Thought Leader Strategy, I/O Commercial Franchise | Remote | May 21, 2026 | Oct 9, 2026 | Senior |
Funding
- Follow-on offering: $50.1M (total, as published), announced Feb 17, 2026. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 18
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma | Phase 2 | Terminated | Apr 12, 2022 | Jun 30, 2025 (actual) |
| NCT05635643 | Study of CHS-114 in Participants With Advanced Solid Tumors | Phase 1 | Active, not recruiting | Dec 15, 2022 | Sep 30, 2026 (estimated) |
| NCT06457503 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Phase 4 | Recruiting | Nov 1, 2024 | 2027-12 (estimated) |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Active, not recruiting | Dec 20, 2024 | 2027-09 (estimated) |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | Phase 1 | Completed | Apr 22, 2020 | May 28, 2025 (actual) |
| NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Phase 1 | Recruiting | Apr 1, 2025 | 2028-01 (estimated) |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Phase 2 | Terminated | Jan 17, 2022 | Apr 5, 2023 (actual) |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Phase 1 | Terminated | Apr 26, 2023 | Jul 31, 2024 (actual) |
| NCT06389526 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Feb 15, 2025 | May 30, 2028 (estimated) |
| NCT04336098 | Study of SRF617 in Patients With Advanced Solid Tumors | Phase 1 | Completed | Mar 16, 2020 | Aug 25, 2023 (actual) |
| NCT04662892 | An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca | Not listed | Unknown status (ClinicalTrials.gov) | Aug 1, 2020 | Nov 1, 2022 (estimated) |
| NCT02489227 | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis | Phase 3 | Completed | 2015-08 | May 6, 2016 (actual) |
| NCT02134210 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) | Phase 3 | Completed | Jun 16, 2014 | Jul 27, 2015 (actual) |
| NCT02115750 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) | Phase 3 | Completed | 2014-05 | 2015-10 (actual) |
| NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) | Phase 3 | Completed | 2015-07 | 2017-09 (actual) |
| NCT02650973 | Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta | Phase 1 | Completed | 2016-02 | 2016-06 (actual) |
| NCT02418104 | Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® | Phase 1 | Completed | 2015-05 | 2015-12 (actual) |
| NCT02385851 | Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim) | Phase 1 | Completed | 2015-02 | 2015-07 (actual) |
Raises and investors new
- InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Coherus Oncology on LinkedIn (search by name, results not checked)